New combo therapy aims to control early lung cancer without surgery

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot or choose not to have surgery. About 45 participants with specific EGFR gene mutations will receive the combination therapy. The goal is to see if this approach improves survival and reduces cancer recurrence.